Vivus, Inc.

10 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Jun 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 14, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 8,536,138	Treatment of pulmonary hypertension with carbonic anhydrase inhibitors In force Ends no later than Jun 13, 2027 · From the USPTO record	In force	Ends no later than Jun 13, 2027	From the USPTO record
US 8,895,057	Escalating dosing regimen for effecting weight loss and treating obesity In force Ends no later than Jun 9, 2028 · From the USPTO record	In force	Ends no later than Jun 9, 2028	From the USPTO record
US 8,895,058	Low dose topiramate/phentermine composition and methods of use thereof In force Ends no later than Jun 9, 2028 · From the USPTO record	In force	Ends no later than Jun 9, 2028	From the USPTO record
US 9,011,906	Escalating dosing regimen for effecting weight loss and treating obesity In force Ends no later than Jun 9, 2028 · From the USPTO record	In force	Ends no later than Jun 9, 2028	From the USPTO record
US 8,580,298	Low dose topiramate/phentermine composition and methods of use thereof In force Term ends May 15, 2029 · From the USPTO record	In force	Term ends May 15, 2029	From the USPTO record
US 8,580,299	Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity In force Term ends Jun 14, 2029 · Medium confidence	In force	Term ends Jun 14, 2029	Medium confidence
US 8,071,557	Treatment of pulmonary hypertension with carbonic anhydrase inhibitors In force Term ends Dec 27, 2029 · From the USPTO record	In force	Term ends Dec 27, 2029	From the USPTO record
US 9,724,327	Methods of Preventing Progression to Type 2 Diabetes Mellitus In force Term ends Oct 8, 2034 · High confidence	In force	Term ends Oct 8, 2034	High confidence
US 10,058,532	Methods of Preventing Progression to Type 2 Diabetes Mellitus In force Term ends Oct 8, 2034 · High confidence	In force	Term ends Oct 8, 2034	High confidence
US 10,028,916	Orally Disintegrating Dosage Form for Administration of Avanafil, and Associated Methods of Manufacture and Use In force Term ends May 15, 2035 · High confidence	In force	Term ends May 15, 2035	High confidence

Also on record, not counted in the 10: 10 lapsed for an unpaid fee · 36 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 22 abandoned · 47 no status recorded

List them